micafungin Side Effects
Also known as: Mycamine
Analysis of 4,779 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
4,779
Death-Related
1,712
35.8% of reports
Hospitalizations
2,379
49.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,712 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 560 |
| OFF LABEL USE | 210 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 197 |
| RESPIRATORY FAILURE | 133 |
| SEPTIC SHOCK | 131 |
| DEATH | 126 |
| SEPSIS | 116 |
| PNEUMONIA | 109 |
| CANDIDA INFECTION | 89 |
| CONDITION AGGRAVATED | 87 |
| PYREXIA | 80 |
| PRODUCT USE IN UNAPPROVED INDICATION | 78 |
| NEUTROPENIA | 76 |
| ACUTE KIDNEY INJURY | 75 |
| RENAL FAILURE | 70 |
| FEBRILE NEUTROPENIA | 63 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 57 |
| ASPERGILLUS INFECTION | 56 |
| DIARRHOEA | 54 |
| HYPOTENSION | 53 |
Reactions in Hospitalization Reports
Top reactions in 2,379 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 497 |
| OFF LABEL USE | 253 |
| PYREXIA | 186 |
| FEBRILE NEUTROPENIA | 185 |
| RESPIRATORY FAILURE | 134 |
| ACUTE KIDNEY INJURY | 133 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 127 |
| PNEUMONIA | 123 |
| SEPSIS | 118 |
| SEPTIC SHOCK | 103 |
| HYPOTENSION | 96 |
| CONDITION AGGRAVATED | 95 |
| DIARRHOEA | 91 |
| PRODUCT USE IN UNAPPROVED INDICATION | 90 |
| NEUTROPENIA | 89 |
| BRONCHOPULMONARY ASPERGILLOSIS | 86 |
| CANDIDA INFECTION | 83 |
| PANCYTOPENIA | 74 |
| ASPERGILLUS INFECTION | 73 |
| INFECTION | 66 |
Nearby — Related Medications
What the FAERS Data Reveals About micafungin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 4,779 voluntary reports linked to micafungin and its brand equivalents (Mycamine), spanning 2004 through 2025. Of those, 1,712 (35.8%) listed death as an outcome and 2,379 (49.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 39% were female and 61% male; age distribution skews toward 45-64, with 1,260 reports in that bracket. The single most reported reaction is drug ineffective with 985 submissions, followed by off label use and pyrexia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.